The cancer market is highly dynamic, creating a new age of discovery and innovation driven by molecular biology, oncogenomics and new methods in cell biology. These innovations will result in high value opportunities to develop newer and more effective therapies, ensuring companies can effectively respond to the increasing prevalence of cancer.

Innovations in Cancer provides a detailed insight into the evolution of the cancer market, the drivers and resistors of innovation and in-depth analysis of advances in both cancer therapeutics and diagnostics to provide a complete picture of how the cancer market will develop over the next five years. It also identifies key alliance and partnering opportunities highlighting companies with specialised capabilities in the discovery and the characterization of next-generation drug targets.

Use this report to understand how the cancer market is developing, identify areas of unmet medical need and align your product pipeline to achieve clinical and commercial success.

Key findings of the report...

In 2000, cancer was responsible for 12% of the 56m deaths world wide. In the same year, 5.3m men and 4.7m women developed a malignant tumor. The World Health Organisation predicts a rise in cancer incidence by 50% by the year 2020, largely due to lifestyle factors.
Roche, Sanofi-Aventis and Amgen were the leading players in the cancer market in 2005, generating sales of $8.5bn, $3.9bn and $3.8bn respectively.
Unmet patient need is the major driver of innovation in both cancer therapeutics and diagnostics. There is significant need for high-sensitivity diagnostic methods to detect the presence of early-stage disease.
Small interfering RNAs are emerging as potential innovative cancer therapies. Whilst the delivery of these molecules remains limited, the number of candidates in development is increasing, with over 25 cancer vaccines in the pipeline.
Competitive pressures and reimbursement issues will increase the demand for better evidential information on efficacy and the need for a diagnostic component to the clinical decision-making process.

Key questions answered in this report

What are the key unmet needs in the cancer market?
How are reimbursement issues affecting innovation in the cancer market?
Who are the leading innovators in the global cancer market?
Why are theranostic considerations becoming increasingly important in the cancer field?
How will scientific advances drive new opportunities in the cancer market in the next 5 years?
What will be the leading innovative cancer drugs and diagnostics in the next 5 years?
What impact will cancer stems cells, siRNA's and vaccines have on drug development to 2011?

Top five reasons to order your copy today

Gain a detailed insight into the evolution of the cancer market, the drivers and resistors of innovation and how this will influence the development of future strategies.
Identify the greatest areas of unmet medical need in the cancer field and how this continues to drive innovation, enabling you to anticipate future trends in the market.
Assess your organisation's position in the market-place, identify competitive innovations and understand how companies are developing better drugs and diagnostics which will displace today's technologies.
Discover the products that are being developed by the leading companies in the cancer market across the 'top four' cancers including breast, colorectal, lung and prostate.
Understand how the use of oncogenomics will allow for better targeting of cancer, creating opportunities for the development of newer more effective products.

Executive Summary
- Current market landscape and dynamics
- Drivers and resistors of innovation
- Innovations in cancer therapeutics
- Innovations in cancer diagnostics
- New R&D strategies in cancer
- The future of the cancer market and conclusions
Chapter 1 Current market landscape and
- dynamics
Summary
- Introduction
- Cancer epidemiology
- Sales by drug class
- Sales by brand
- Sales by company
- Sales by country
- Gold standard treatments
- Lung cancer
- Colorectal cancer
- Breast cancer
- Ovarian
- Uterine
- Leukemia
- Prostate
- Pancreatic
- Lymphomas
- Unmet need
- Innovation in the cancer market
- Targeted therapy
- Cancer diagnostics
Chapter 2 Drivers and resistors of
- innovation
Summary
- Introduction
- Drivers of innovation
- Cancer statistics
- Need
- Risk
- Scientific advances
- Diagnostics
- Resistors
- Market fragmentation
- Reimbursement
Chapter 3 Innovations in cancer
- therapeutics
Summary
- Introduction
- Key trends
- Key innovations
- Targeted therapies
- Cancer vaccines
- Small interfering RNAs
- Pipeline
- Addressing unmet need
Chapter 4 Innovations in cancer diagnostics
Summary
- Introduction
- Cancer biomarkers
- Predicting cancer
- Diagnostic innovations by indication
- Lung
- Colon & rectum
- Breast
- Ovary
- Uterus and cervix
- Leukemia
- Prostate
- Pancreas
- Lymphomas
Chapter 5 New R&D strategies in cancer
Summary
- Introduction
- Background
- Oncogenomics
- Scientific approaches
- Small interfering RNA
- Biologicals
- Gene expression and biomarkers
- Arrays
- Drug delivery
- Cancer stem cells
- Looking ahead
Chapter 6 The future of the cancer market
- and conclusions
Summary
- Introduction
- Key trends
- The future
Chapter 7 Appendix
- Index
List of Figures
- Figure 1.1: Incidence per cancer indication and country, 2005
- Figure 2.2: Drivers and resistors of innovation in the cancer market
- Figure 3.3: Companies developing new therapeutics for the "top four" cancers, 2007
- Figure 3.4: Numbers of drugs in development for the "top four" cancers, 2006
- Figure 3.5: Top companies developing therapeutics for the "top four" cancers, 2006
- Figure 3.6: Phase I-III pipeline for the "top four" cancers, 2006
- Figure 4.7: Categorization of cancer diagnostic tests
- Figure 4.8: Overview of diagnostics for 10 leading cancers, 2006
List of Tables
- Table 1.1: Incidence of 9 major tumor types in the 7 major markets, 2005
- Table 1.2: Global cancer market sales by drug class, 2004-05
- Table 1.3: Top 20 global cancer brands, 2004-05
- Table 1.4: Top 20 cancer companies by global sales, 2004-05
- Table 1.5: Global cancer market sales by drug class, 2004-05
- Table 1.6: Gold standard treatments and limitations
- Table 2.7: The World Cancer Report - 5 year survival rates
- Table 2.8: Incidence and prevalence for 9 cancers in 2005, for 7 major markets (US, Japan,
- France, Germany, Italy, Spain, UK)
- Table 2.9: Pipeline cancer drugs by indication, 2006
- Table 2.10: Data indicating unmet need in cancers based on the numbers of patients globally, 2002
- Table 3.11: Cancer vaccine pipeline, 2006
- Table 3.12: siRNA drug pipeline, 2006

Pharmaceutical Market Research

Innovations in Cancer